Platform & Pipeline

Overview

Our Dynamic Tumor Targeting™ Platform creates NDCs with the aim of providing safer and/or more effective therapies for patients living with cancer. This clinically validated platform is a product engine that has thus far generated a lead candidate, CRLX101, and a second candidate, CRLX301, and has the potential to expand our pipeline, alone and in combination with partners.